Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation. Hosoya K, Ozasa H, Yoshida H, Ajimizu H, et al. Cancer Sci 2025;116:1883-1896.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hosoya K, Ozasa H, Yoshida H, Ajimizu H, et al. Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation. Cancer Sci 2025;116:1883-1896.
PMID: 40202586